文献速递妇科

分子生物标志物人乳头瘤病毒(HPV)E6癌蛋白在宫颈癌筛查中的作用

Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening.
PubMed 文献 · Gynecol Oncol · 2020-07-14

这项前瞻性研究于2018年6月至2019年6月纳入235名21-65岁女性,在妇科肿瘤门诊行醋酸肉眼观察(VIA)、细胞学、E6癌蛋白检测和阴道镜检查,比较E6癌蛋白检测与其他筛查方法的性能。E6癌蛋白检测特异性(97%)和阳性预测值(75%)最高,对CIN3+的敏感性(52%)显著高于细胞学(25%)但低于VIA(74%)。作者认为E6癌蛋白检测特异性高,是减少VIA假阳性所致阴道镜转诊的有效分流试验。

要点

  • E6癌蛋白阳性率为6.8%(n=16),其中HPV 16阳性占81.25%、HPV 18阳性占18.75%。
  • E6癌蛋白检测特异性97%、PPV 75%,高于VIA(42%、18%)、细胞学(95%、46%)和阴道镜(94%、59%)。
  • E6癌蛋白检测对CIN3+的敏感性52%,显著高于细胞学25%,但低于VIA 74%。

核心结论

  • HPV E6癌蛋白检测特异性高,是减少因VIA大量假阳性结果而转诊阴道镜的有效分流试验。

研究设计与样本

  • 前瞻性研究,2018年6月至2019年6月纳入235名21-65岁因妇科肿瘤门诊就诊的女性。
  • 所有对象行VIA、细胞学、E6癌蛋白检测和阴道镜检查,任一试验阳性或可疑者经阴道镜活检进一步评估。
  • 采用McNemar检验比较E6癌蛋白检测与其他筛查试验的性能。

主要发现

  • E6癌蛋白阳性率为6.8%(n=16),其中HPV 16阳性占81.25%、HPV 18阳性占18.75%。
  • VIA阳性病例(n=100)中E6癌蛋白阳性率为9%(p < .001)。
  • 组织病理学确诊慢性宫颈炎、CIN I、CIN II、CIN III和浸润性宫颈癌中,E6检测阳性率分别为2.8%、4.7%、25%、50%和100%。
  • E6癌蛋白检测特异性97%、PPV 75%,高于VIA(42%、18%)、细胞学(95%、46%)和阴道镜(94%、59%)。
  • E6癌蛋白检测对CIN3+的敏感性52%,显著高于细胞学25%,但低于VIA 74%。

关键数值与推荐

  • E6癌蛋白检测特异性97%、PPV 75%。
  • VIA特异性42%、PPV 18%;细胞学特异性95%、PPV 46%;阴道镜特异性94%、PPV 59%。
  • E6癌蛋白检测对CIN3+敏感性52%,细胞学25%,VIA 74%。

临床怎么用

  • 作者认为HPV E6癌蛋白检测特异性高,可作为减少VIA假阳性所致阴道镜转诊的有效分流试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Onco E6™ Cervical Test, based on detection of the E6 oncoprotein of HPV 16 and 18 genotypes is evaluated as a screen for the early detection cervical neoplasia in resource-limited countries. METHODS: This prospective study from June 2018 to June 2019 evaluated 235 women aged 21-65 years, who came to Gynaecological Oncology Outpatient Department by VIA, cytology, E6 oncoprotein test and by colposcopy. Screen-positive women by any of the tests or women with suspicious findings were further evaluated by biopsy at colposcopy. The McNemar test was used to compare the performance of E6 oncoprotein test with other screening tests. RESULTS: The E6 oncoprotein positivity rate was 6.8% (n = 16) with 81.25% HPV 16 positive and 18.75% HPV 18 positive. Among VIA positive cases (n = 100), E6 oncoprotein was positive in 9% (p < .001). In histopathology confirmed chronic cervicitis, CIN I, CIN II, CIN III and invasive cervical cancer, E6 test was positive for 2.8%, 4.7%, 25%, 50% and 100% respectively. E6 oncoprotein test had the highest specificity and Positive Predictive Value (PPV; 97% and 75%) compared to VIA (42% and 18%), cytology (95% and 46%) and colposcopy (94% and 59%). Sensitivity of the E6 oncoprotein test for detection of CIN3+ was significantly higher than that of cytology (52% VS 25%) but lower than that of VIA (52% VS 74%). CONCLUSIONS: The HPV E6 oncoprotein test is highly specific and is an effective triage test to reduce colposcopy referrals for the large number of false positive test outcomes seen with VIA.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ara R, Khatun S, Pervin S, et al. Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening. Gynecol Oncol. 2020. PMID: 32680634. doi:10.1016/j.ygyno.2020.06.496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。